BrECADD regimen provides significantly higher rates of gonadal function recovery than eBEACOPP in both men and women with advanced-stage classic Hodgkin lymphoma.
Parenthood rates post-treatment are significantly higher in men treated with BrECADD; women show a numerical but non-significant benefit.
BrECADD maintains high efficacy and acute tolerability, with reduced treatment-related morbidity compared to eBEACOPP.
These findings support BrECADD as the preferred first-line therapy for patients with fertility concerns.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.